600056 中国医药
2026/09 - 九个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入24,989,322-3.50%35,361,62235,243,41438,824,43137,592,650
减:营业总成本24,280,070-2.81%34,112,38834,019,35637,501,89536,137,940
    其中:营业成本22,384,446-3.53%31,647,84731,459,67134,440,81432,845,786
               财务费用163,170366.02%110,016211,480112,038138,317
               资产减值损失(7,177)11,386.31%(150,704)(180,391)(13,539)(280,660)
公允价值变动收益74-98.75%(2,211)127,4679851,922
投资收益17,34334.45%(68,010)(64,072)(15,792)51,001
    其中:对联营企业和合营企业的投资收益46,92213.37%31,36718,73677,04393,219
营业利润616,230-25.19%1,022,988986,5931,672,3341,199,698
利润总额615,200-25.20%999,2951,008,1561,640,5561,196,127
减:所得税费用224,220-4.07%324,659274,343398,435307,699
净利润390,980-33.59%674,636733,8141,242,120888,428
减:非控股权益99,866-25.44%201,407151,232194,081152,827
股东净利润291,114-35.99%473,229582,5821,048,039735,601

市场价值指针
每股收益 (元) *0.195-35.99%0.3160.3900.7010.492
每股派息 (元) *----0.0950.1070.2100.148
每股净资产 (元) *8.0371.43%7.9127.9027.7287.230
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容